Combinatiechemotherapie en ponatinibhydrochloride bij de behandeling van patiënten met acute lymfoblastische leukemie
Fase II-studie van combinatie van hyper-CVAD en ponatinib bij patiënten met Philadelphia (PH)-chromosoompositieve en/of BCR-ABL-positieve acute lymfoblastische leukemie (ALL)
This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
- Acute lymfatische leukemie
- Blastfase chronische myeloïde leukemie, BCR-ABL1 positief
- Philadelphia-chromosoom positief
- B acute lymfoblastische leukemie met t(9;22)(q34.1;q11.2); BKR-ABL1
- Onbehandelde volwassen acute lymfoblastische leukemie
- Versnelde fase chronische myeloïde leukemie, BCR-ABL1 positief
- Volwassen acute lymfoblastische leukemie in volledige remissie
Interventie / Behandeling
Interventie / Behandeling
- Ander: Laboratory Biomarker Analysis
- Geneesmiddel: Cyclophosphamide
- Geneesmiddel: Doxorubicin Hydrochloride
- Geneesmiddel: Prednisone
- Geneesmiddel: Cytarabine
- Geneesmiddel: Dexamethasone
- Geneesmiddel: Doxorubicin
- Geneesmiddel: Methotrexate
- Geneesmiddel: Ponatinib
- Geneesmiddel: Ponatinib Hydrochloride
- Biologisch: Rituximab
- Geneesmiddel: Vincristine
- Geneesmiddel: Vincristine Sulfate
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To evaluate the clinical efficacy (event-free survival) of an intensive short-term chemotherapy regimen (hyperfractionated cyclophosphamide-vincristine sulfate-Adriamycin [doxorubicin hydrochloride]-dexamethasone [hyper-CVAD] program) given in combination with the tyrosine kinase inhibitor ponatinib hydrochloride (ponatinib) for Philadelphia (Ph)-positive and/or BCR-ABL-positive acute lymphoblastic leukemia (ALL).
II. To evaluate other clinical efficacy endpoints (overall response rate and survival) and safety of the regimen.
OUTLINE:
ODD CYCLES (1, 3, 5, and 7): Patients receive cyclophosphamide intravenously (IV) over 3 hours every 12 hours on days 1-3, doxorubicin hydrochloride IV continuously over 24 hours on day 4, vincristine sulfate IV over 30 minutes on days 1 and 11, dexamethasone IV over 30 minutes or orally (PO) once daily (QD) on days 1-4 and 11-14, and ponatinib hydrochloride PO QD on days 1-14 of cycle 1 and continuously in cycles 3, 5, and 7. Patients with CD20 expression may also receive rituximab IV on days 1 and 11 of cycle 1 and 3. Treatment repeats every 3-4 weeks for up to 8 cycle in the absence of disease progression or unacceptable toxicity.
EVEN CYCLES (2, 4, 6, and 8): Patients receive methotrexate IV over 24 hours on day 1, ponatinib hydrochloride PO QD continuously, and cytarabine IV over 3 hours every 12 hours on days 2 and 3. Patients with CD20 expression may also receive rituximab IV on days 1 and 8 of cycle 2 and 4. Treatment repeats every 3-4 weeks for up to 8 cycle in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive vincristine sulfate IV on day 1, prednisone PO daily on days 1-5, and ponatinib hydrochloride PO QD on days 1-28. Cycle repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6 months for up to 24 months.
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- M D Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Diagnosis of one of the following:
-
Previously untreated Ph-positive ALL [either t(9;22) and/or bcr-abl positive] (includes patients initiated on first course of hyper-CVAD before cytogenetics known) or with lymphoid accelerated or blast phase chronic myelogenous leukemia (CML)
-
Previously treated Ph-positive ALL or CML (in accelerated phase or blast phase), after 1-2 courses of chemotherapy with or without other tyrosine kinase inhibitors (TKIs)
- If they achieved complete response (CR), they are assessable only for event-free and overall survival, or
- If they failed to achieve CR, they are assessable for CR, event-free, and overall survival
-
-
Performance status ≤ 2 (Eastern Cooperative Oncology Group [ECOG] scale, Appendix E)
-
Adequate liver function as defined by the following criteria:
-
Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome
-
Alanine aminotransferase (ALT) ≤ 2 x ULN
-
Aspartate aminotransferase (AST) ≤ 2.5 x ULN
-
Adequate pancreatic function as defined by the following criteria:
-
Serum lipase and amylase ≤ 1.5 x ULN
-
For females of childbearing potential, a negative pregnancy test must be documented prior to randomization
-
Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment
-
Adequate cardiac function as assessed clinically by history and physical examination
-
Signed informed consent
Exclusion Criteria:
-
Active serious infection not controlled by oral or intravenous antibiotics
-
History of acute pancreatitis within 1 year of study or history of chronic pancreatitis
-
History of alcohol abuse
-
Uncontrolled hypertriglyceridemia (triglycerides > 450 mg/dL)
-
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year
-
Active grade III-V cardiac failure as defined by the New York Heart Association criteria
-
Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- Any history of myocardial infarction (MI), stroke, or revascularization
- Unstable angina or transient ischemic attack prior to enrollment
- Congestive heart failure prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards prior to enrollment
- Diagnosed or suspected congenital long QT syndrome
- Any history of clinically significant atrial or ventricular arrhythmias (such as atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or torsades de pointes) as determined by the treating physician
- Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 470 msec) unless corrected after electrolyte replacement
- Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
- Uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 140 mmHg); patients with hypertension should be under treatment on study entry to effect blood pressure control
-
Patients currently taking drugs that are generally accepted to have a risk of causing torsades de pointes (unless these can be changed to acceptable alternatives)
-
Taking any medications or herbal supplements that are known to be strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) within at least 14 days before the first dose of ponatinib
-
Prior history of treatment with ponatinibfor > 1 month; patient who has been treated with ponatinib for 1 month prior starting the treatment is eligible
-
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator; patient who has been treated with ponatinib for 1 month prior starting the treatment is eligible
-
Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception; women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months; in addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control
-
History of significant bleeding disorder unrelated to cancer, including:
- Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
- Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
-
Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Treatment (combination chemotherapy, ponatinib hydrochloride)
See Detailed Description. |
Correlative studies Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV or PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Event-free survival
Tijdsspanne: The time from the start of the treatment until any failure (resistant disease, relapse, or death), assessed up to 24 months
|
Kaplan-Meier survival curves will be constructed. |
The time from the start of the treatment until any failure (resistant disease, relapse, or death), assessed up to 24 months
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Complete response rate
Tijdsspanne: Up to 24 months after completion of study treatment
|
Complete response is defined as achieving bone marrow blasts =< 5% AND platelets >= 100 AND absolute neutrophil count >= 1000 within 3 courses of treatment. The method of Thall, Simon, and Estey will be employed to perform short-term interim efficacy. Response rate and its corresponding 95% confidence interval will be provided at the end of the study. |
Up to 24 months after completion of study treatment
|
|
Incidence of grade 3-4 toxicity according to the M.D. Anderson Leukemia-specific Adverse Event Recording and Reporting Guidelines
Tijdsspanne: Up to 24 months
|
The method of Thall, Simon, and Estey will be employed to perform short-term interim safety monitoring. Will be summarized in frequency tables or in the form of mean, standard deviation, and range where appropriate. Toxicity rate and its corresponding 95% confidence interval will be provided at the end of the study. |
Up to 24 months
|
|
Overall survival
Tijdsspanne: Up to 24 months after completion of study treatment
|
Kaplan-Meier survival curves will be constructed. Survival rates at specific time points will be estimated along with corresponding 95% confidence intervals. |
Up to 24 months after completion of study treatment
|
|
Disease-specific survival
Tijdsspanne: Up to 24 months after completion of study treatment
|
Kaplan-Meier survival curves will be constructed. Survival rates at specific time points will be estimated along with corresponding 95% confidence intervals. |
Up to 24 months after completion of study treatment
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Elias Jabbour, M.D. Anderson Cancer Center
Publicaties en nuttige links
Algemene publicaties
- Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.
- Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov;16(15):1547-1555. doi: 10.1016/S1470-2045(15)00207-7. Epub 2015 Sep 30.
- Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 Mar;98(3):493-501. doi: 10.1002/ajh.26816. Epub 2023 Jan 4.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Chronische ziekte
- Ziekte attributen
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Neoplastische processen
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Leukemie, myeloïde
- Beenmergziekten
- Leukemie, Lymfoïde
- Leukemie
- Myeloproliferatieve aandoeningen
- Leukemie, Myelogeen, Chronisch, BCR-ABL Positief
- Celtransformatie, neoplastisch
- Kankerverwekkendheid
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- Voorlopercel lymfoblastische leukemie-lymfoom
- Ontploffingscrisis
- Leukemie, myeloïde, versnelde fase
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Nucleïnezuren, nucleotiden en nucleosiden
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Koolhydraten
- Alkaloïden
- Polycyclische aromatische koolwaterstoffen
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Glycosiden
- Indolen
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Zwangerschap
- Zwangere
- Steroïden
- Verbindingen met gefuseerde ring
- Steroïden, gefluoreerd
- Benzeenderivaten
- Sulfonzuren
- Zwavelzuren
- Fosforamide mosterd
- Stikstofmosterdverbindingen
- Mosterdverbindingen
- Koolwaterstoffen, gehalogeneerd
- Fosforamides
- Organofosforverbindingen
- Nucleosiden
- Pterins
- Pteridines
- Zwangerschap
- Zwangerschap
- Vinca -alkaloïden
- Secologanin tryptamine alkaloïden
- Indol alkaloïden
- Indolizidines
- Indolizines
- Arabinonucleosides
- Aminopterine
- Antracyclines
- Naftacenes
- Aminoglycosides
- Antilichamen, monoklonaal, van murine afgeleid
- Daunorubicine
- Benzenesulfonaten
- Arylsulfonaten
- Arylsulfonzuren
- Rituximab
- Dexamethason
- Methotrexaat
- Prednison
- Cyclofosfamide
- Cytarabine
- Doxorubicine
- Vincristine
- Calciumdobesilaat
- Dexamethason 21-fosfaat
- CT-P10
- deltacorteen
- prednylidene
- Merphos
- auricularum
- Dexamethason acetaat
- ponatinib
Andere studie-ID-nummers
Andere studie-ID-nummers
- 2011-0030
- 2011-0030 (Andere identificatie: M D Anderson Cancer Center)
- NCI-2011-02941 (Register-ID: CTRP (Clinical Trial Reporting Program))
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .